Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 13/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | ARAF | P10398 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15859935 | 0.82 | KDM4E (0.55) | DDR1KDM4EALDH1A1MAPT | |
| SCHEMBL15381987 | 0.79 | DDR1 (0.49) | DDR1ABL1KDM1ARIPK2LCK | |
| SCHEMBL589421 | 0.78 | NR1H2 (0.61) | DDR1ABL1RIPK2LCKFYN | |
| SCHEMBL28001612 | 0.78 | MLNR (0.42) | KDM4EALDH1A1MAPTABL1 | |
| SCHEMBL28816963 | 0.78 | MLNR (0.42) | KDM4EALDH1A1MAPTABL1 | |
| SCHEMBL589420 | 0.78 | NR1H2 (0.61) | DDR1ABL1RIPK2LCKFYN | |
| SCHEMBL15687979 | 0.78 | NR1H2 (0.61) | DDR1ABL1RIPK2LCKFYN | |
| SCHEMBL27081642 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1 | |
| SCHEMBL282609 | 0.76 | HRH4 (0.39) | HRH3 | |
| SCHEMBL1655534 | 0.76 | ALDH1A1 (0.46) | KDM4EALDH1A1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143716-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | claimed |
| US-20150313900-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | claimed |
| US-9061029-B2 | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | claimed |
| US-20140350037-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | claimed |
| US-20130267549-A1 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | claimed |
| US-20120289528-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | claimed |
| EP-2501384-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | Novartis AG (CH) | 2012-09-26 | — | — | EP | claimed |
| EP-2490690-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | Novartis AG (CH) | 2012-08-29 | — | — | EP | claimed |
| US-20120202836-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | claimed |
| US-20120015968-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE LEUCINE ZIPPER-AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK) | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | claimed |
| JP-2011528015-A | — | — | 2011-11-10 | — | — | JP | claimed |
| WO-2011062927-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | claimed |
| US-20110124670-A1 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | claimed |
| WO-2011050120-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | claimed |
| EP-2300014-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF FIBROSIS | Novartis AG (CH) | 2011-03-30 | — | — | EP | claimed |
| WO-2010007034-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF FIBROSIS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | claimed |
| US-20170143716-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20150313900-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| WO-2010100248-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK) | NOVARTIS AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010007034-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF FIBROSIS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350037-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, PDGFRA | DDR1 2/4885KDM4E 3565/4885ALDH1A1 1225/4885 |
| US-20120015968-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE LEUCINE ZIPPER-AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK) | MELK, MINK1, ZFX | DDR1 3377/4885KDM4E 2240/4885ALDH1A1 2961/4885 |
| US-20120289528-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, PDGFRA | DDR1 2/4885KDM4E 3784/4885ALDH1A1 987/4885 |
| US-20120202836-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, PDGFRA | DDR1 2/4885KDM4E 3836/4885ALDH1A1 1124/4885 |
| US-20150313900-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, PDGFRB | DDR1 2/4885KDM4E 1288/4885ALDH1A1 1027/4885 |
| US-20130267549-A1 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis | AGTR1, AGTR2, ACE | DDR1 1326/4885KDM4E 3135/4885ALDH1A1 140/4885 |
| US-20110124670-A1 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis | AGTR1, AGTR2, ACE | DDR1 1414/4885KDM4E 3167/4885ALDH1A1 147/4885 |
| US-20170143716-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, ABL2 | DDR1 2/4885KDM4E 3282/4885ALDH1A1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.